Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Short-term Investments (2016 - 2025)

UroGen Pharma's Short-term Investments history spans 10 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 25.46% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 25.46%, while the annual FY2025 figure was $1.3 million, 25.46% up from the prior year.
  • Short-term Investments reached $1.3 million in Q4 2025 per URGN's latest filing, down from $37.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $124.7 million in Q3 2024 to a low of $550000.0 in Q1 2022.
  • Average Short-term Investments over 5 years is $28.0 million, with a median of $14.9 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: tumbled 98.45% in 2022, then skyrocketed 15158.14% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $1.2 million in 2021, then soared by 3534.26% to $44.6 million in 2022, then decreased by 5.81% to $42.0 million in 2023, then crashed by 97.44% to $1.1 million in 2024, then grew by 25.46% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Short-term Investments are $1.3 million (Q4 2025), $37.0 million (Q3 2025), and $64.0 million (Q2 2025).